



February 27, 2017

## Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in three upcoming investor conferences. The details for the three conferences are:

- ▮ **The Cowen and Company 37th Annual Health Care Conference at the Boston Marriott Copley Place on March 6, 2017.** Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will make a presentation at 3:20 pm ET.
- ▮ **The 29th Annual ROTH Conference at the Ritz Carlton Hotel in Orange County, California on March 13, 2017.** Michael A. Metzger, President and Chief Operating Officer of Syndax, will make a presentation at 4:30 pm PT.
- ▮ **The Oppenheimer 27th Annual Healthcare Conference at the Westin New York Grand Central on March 22, 2017.** Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will make a presentation at 10:20 am ET.

A live webcast of these presentations can be accessed from the Investor section of the Company's website at [www.syndax.com](http://www.syndax.com), where a replay of the events will also be available for a limited time.

### About Syndax Pharmaceuticals, Inc.

Syndax is a clinical stage biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Syndax is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma; with Genentech, Inc. for TNBC; and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352 is being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers. For more information on Syndax, please visit [www.syndax.com](http://www.syndax.com).

Investor Contacts  
Heather Savelle  
Argot Partners  
[heather@argotpartners.com](mailto:heather@argotpartners.com)  
Tel 646.395.3734

Media Contact  
Eliza Schleifstein  
Argot Partners  
[eliza@argotpartners.com](mailto:eliza@argotpartners.com)  
Tel 973.361.1546